Meeting
2019 Gastrointestinal Cancers Symposium
Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab.
Authors
Justin Moser
University of Utah Huntsman Cancer Institute, Salt Lake City, UT
Justin Moser , Benjamin Solomon , Christopher Duane Nevala-Plagemann , Glynn Weldon Gilcrease , Jonathan R. Whisenant , Ignacio Garrido-Laguna
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Translational Research
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 69)
DOI
10.1200/JCO.2019.37.4_suppl.69
Abstract #
69
Poster Bd #
G19
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
A phase II study of nab-paclitaxel plus ramucirumab for the second-line treatment of patients with metastatic gastroesophageal cancer.
First Author: Johanna C. Bendell
Poster
2019 ASCO Annual Meeting
RAP: A phase II trial with ramucirumab, avelumab, and paclitaxel as second line treatment in gastro-esophageal adenocarcinoma of the arbeitsgemeinschaft internistische onkologie (AIO).
First Author: Anica Högner
Poster
2018 ASCO Annual Meeting
Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).
First Author: Whitney Paige Kirschbrown
Poster
2018 Gastrointestinal Cancers Symposium
Patterns of chemotherapy (CT) use in a U.S.-wide cohort of patients (pts) with metastatic gastric cancer (MGC).
First Author: Thomas Adam Abrams